Remco Vellinga

Dr. Remco Vellinga

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in British Journal of Anaesthesia
Verified
Journal Article
Open access
RVRemco Vellinga
Remco Vellinga
LHLaura N. Hannivoort
Laura N. Hannivoort
MIMichele Introna
Michele Introna
DTDaan J. Touw
Daan J. Touw
AAAnthony R. Absalom
Anthony R. Absalom
MSMichel M.R. F. Struys
Michel M.R. F. Struys
Target-controlled infusion (TCI) systems incorporating pharmacokinetic (PK) or PK-pharmacodynamic (PK-PD) models can be used to facilitate drug administration. Existing models were developed using data from select populations, the use of which is, strictly speaking, limited to these populations. Recently a propofol PK-PD model was developed for a broad population range. The aim of the study was to prospectively validate this model in children, adults, older subjects, and obese adults undergoing general anaesthesia. The 25 subjects included in each of four groups were stratified by age and weight. Subjects received propofol through TCI with the Eleveld model, titrated to a bispectral index (BIS) of 40-60. Arterial blood samples were collected at 5, 10, 20, 30, 40, and 60 min after the start of propofol infusion, and every 30 min thereafter, to a maximum of 10 samples. BIS was recorded continuously. Predictive performance was assessed using the Varvel criteria. For PK, the Eleveld model showed a bias < ±20% in children, adults, and obese adults, but a greater bias (-27%) in older subjects. Precision was <30% in all groups. For PD, the bias and wobble were <5 BIS units and the precision was close to 10 BIS units in all groups. Anaesthetists were able to achieve intraoperative BIS values of 40-60 using effect-site target concentrations about 85-140% of the age-adjusted Ce50. The Eleveld propofol PK-PD model showed predictive precision <30% for arterial plasma concentrations and BIS predictions with a low (population) bias when used in TCI in clinical anaesthesia practice.

15 January 2025 in Anesthesiology
Verified
Journal Article
Open access
RVRemco Vellinga
Remco Vellinga
JKJeroen V. Koomen
Jeroen V. Koomen
DEDouglas J. Eleveld
Douglas J. Eleveld
TSThomas Stöhr
Thomas Stöhr
MPMarija Pesic
Marija Pesic
PCPieter J. Colin
Pieter J. Colin
Background: Synergistic effects between opioids and remimazolam on Bispectral Index (BIS) and Modified Observer’s Assessment of Alertness and Sedation (MOAAS) score were previously described. This study aimed to characterize the influence of remifentanil on the sedative properties of remimazolam as measured by MOAAS, BIS, and tolerance to laryngoscopy or tetanic stimulation (TOL or TOTS) and to determine target concentrations that maximize MOAAS 2 or 3. Methods: A three-period, crossover, dose-ranging clinical trial was performed in 24 healthy volunteers. In all periods, remimazolam was administered using a step-up and step-down target controlled infusion protocol (50 to 2,000 ng/ml). Stable remifentanil target concentrations of 0.5 ng/ml and 0.1 to 4.0 ng/ml were maintained in periods 2 and 3, respectively. Remifentanil, remimazolam, and CNS7054 (metabolite) concentrations and MOAAS, BIS, TOL, and TOTS were collected in each step of the target controlled infusion protocol. Data were analyzed using nonlinear mixed-effects models, where P ≤ 0.01 was considered significant. Results: Remifentanil reduced the apparent clearance of CNS7054 with a half-maximum inhibition at 8.0 ng/ml (95% CI, 5.5 to 13.4 ng/ml). A pharmacodynamic interaction was detected on all endpoints. Simulations indicate that the probability of observing a MOAAS 2 or 3 is highest at remimazolam target concentration of 275, 250, or 200 ng/ml combined with 0, 0.1, or 0.5 ng/ml remifentanil resulting in probabilities of 45%, 45%, and 44%, respectively. Additionally, simulations indicate that the highest probability of observing TOTS and TOL was 93.3% and 85.5%, respectively, at the highest studied target concentrations. Conclusions: A pharmacokinetic and pharmacodynamic drug–drug interaction between remimazolam and remifentanil was quantified in this clinical trial. Appropriate target concentrations for MOAAS and BIS could be estimated, but for TOL and TOTS, the trial design did not allow to fully characterize the exposure–response relationship.

8 August 2023 in Current Opinion in Anaesthesiology
Verified
Journal Article
Open access
RVRemco Vellinga
Remco Vellinga
DEDouglas J. Eleveld
Douglas J. Eleveld
MSMichel M.R.F. Struys
Michel M.R.F. Struys
JBJohannes P. van Den Berg
Johannes P. van Den Berg
Purpose of review: There are various pharmacokinetic-dynamic models available, which describe the time course of drug concentration and effect and which can be incorporated into target-controlled infusion (TCI) systems. For anesthesia and sedation, most of these models are derived from narrow patient populations, which restricts applicability for the overall population, including (small) children, elderly, and obese patients. This forces clinicians to select specific models for specific populations. Recent findings: Recently, general purpose models have been developed for propofol and remifentanil using data from multiple studies and broad, diverse patient groups. General-purpose models might reduce the risks associated with extrapolation, incorrect usage, and unfamiliarity with a specific TCI-model, as they offer less restrictive boundaries (i.e., the patient “doesn’t fit in the selected model”) compared with the earlier, simpler models. Extrapolation of a model can lead to delayed recovery or inadequate anesthesia. If multiple models for the same drug are implemented in the pump, it is possible to select the wrong model for that specific case; this can be overcome with one general purpose model implemented in the pump. Summary: This article examines the usability of these general-purpose models in relation to the more traditional models.

Verified
Journal Article
Open access
PDF file
RVRemco Vellinga
Remco Vellinga
BVBeatrijs I. Valk
Beatrijs I. Valk
AAAnthony R. Absalom
Anthony R. Absalom
MSMichel MRF Struys
Michel MRF Struys
CBClemens R. M. Barends
Clemens R. M. Barends
New anaesthetic drugs and new methods to administer anaesthetic drugs are continually becoming available, and the development of new PK-PD models furthers the possibilities of using arget controlled infusion (TCI) for anaesthesia. Additionally, new applications of existing anaesthetic drugs are being investigated. This review describes the current situation of anaesthetic drug development and methods of administration, and what can be expected in the near future.

19 December 2023 in Journal of Clinical Monitoring and Computing
Verified
Journal Article
Closed access
PDF file
RVRemco Vellinga
Remco Vellinga
MIMichele Introna
Michele Introna
KAKai van Amsterdam
Kai van Amsterdam
XZX. Y. Tommy Zhou
X. Y. Tommy Zhou
TSTom De Smet
Tom De Smet
JBJohannes P. van Den Berg
Johannes P. van Den Berg

1 July 2021 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
RVRemco Vellinga
Remco Vellinga
LHLaura N. Hannivoort
Laura N. Hannivoort
JKJeroen V. Koomen
Jeroen V. Koomen
PCPieter Colin
Pieter Colin
AAAnthony R. Absalom
Anthony R. Absalom
DEDouglas J. Eleveld
Douglas J. Eleveld